Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Company Details
- Employees
- 70
- Founded
- -
- Address
- Shield Therapeutics Plc, Northern Design Centre,united Kingdom
- in****@****ics.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- shieldtherapeutics.com
- Keywords
- Anaemia, Renal disease, IBD.
- HQ
- Gateshead Quays
Shield Therapeutics Plc Questions
Shield Therapeutics Plc's website is shieldtherapeutics.com
Shield Therapeutics Plc's LinkedIn profile is https://uk.linkedin.com/company/shield-therapeutics
Shield Therapeutics Plc has
70 employees.
View email and phone details for 70
employees at Shield Therapeutics Plc.
Shield Therapeutics Plc's industry is
Pharmaceutical Manufacturing
Shield Therapeutics Plc's top competitors are
Pfizer,
Vertex Pharmaceuticals,
Syneos Health,
Rxsalespros,
Madrigal Pharmaceuticals,
Abbvie,
Silence Therapeutics Plc,
Viatris,
Amgen,
Alnylam Pharmaceuticals.
Shield Therapeutics Plc's support email address is info@shieldtherapeutics.com
Shield Therapeutics Plc's categories are Pharmaceutical Manufacturing
Shield Therapeutics Plc's founding year is 2008
